PL1891038T3 - Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego - Google Patents
Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowegoInfo
- Publication number
- PL1891038T3 PL1891038T3 PL06759481T PL06759481T PL1891038T3 PL 1891038 T3 PL1891038 T3 PL 1891038T3 PL 06759481 T PL06759481 T PL 06759481T PL 06759481 T PL06759481 T PL 06759481T PL 1891038 T3 PL1891038 T3 PL 1891038T3
- Authority
- PL
- Poland
- Prior art keywords
- arylpyrrolidines
- substituted
- androgen receptor
- compound
- formula
- Prior art date
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 208000036119 Frailty Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68091105P | 2005-05-13 | 2005-05-13 | |
| PCT/US2006/018061 WO2006124447A2 (en) | 2005-05-13 | 2006-05-10 | Substituted n-arylpyrrolidines as selective androgen receptor modulators |
| EP06759481A EP1891038B1 (en) | 2005-05-13 | 2006-05-10 | Substituted n-arylpyrrolidines as selective androgen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1891038T3 true PL1891038T3 (pl) | 2009-04-30 |
Family
ID=37057376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06759481T PL1891038T3 (pl) | 2005-05-13 | 2006-05-10 | Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7807691B2 (enExample) |
| EP (1) | EP1891038B1 (enExample) |
| JP (1) | JP5089578B2 (enExample) |
| CN (1) | CN101175747B (enExample) |
| AT (1) | ATE412647T1 (enExample) |
| AU (1) | AU2006247738A1 (enExample) |
| BR (1) | BRPI0610183A2 (enExample) |
| CA (1) | CA2608419A1 (enExample) |
| CY (1) | CY1108690T1 (enExample) |
| DE (1) | DE602006003432D1 (enExample) |
| DK (1) | DK1891038T3 (enExample) |
| ES (1) | ES2314922T3 (enExample) |
| MX (1) | MX2007014053A (enExample) |
| PL (1) | PL1891038T3 (enExample) |
| PT (1) | PT1891038E (enExample) |
| SI (1) | SI1891038T1 (enExample) |
| WO (1) | WO2006124447A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1911743B8 (en) * | 2005-08-01 | 2013-01-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
| US8013008B2 (en) | 2006-11-30 | 2011-09-06 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| CA2695852C (en) | 2007-08-07 | 2017-01-03 | Takeda Pharmaceutical Company Limited | Cyclic amine compounds |
| DK2222636T3 (da) | 2007-12-21 | 2013-06-03 | Ligand Pharm Inc | Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf |
| BRPI0907844B8 (pt) | 2008-02-22 | 2021-05-25 | Radius Health Inc | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| WO2009131196A1 (ja) * | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | 置換ピロリジン誘導体およびその用途 |
| WO2009133861A1 (ja) * | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
| JP5964756B2 (ja) | 2010-02-04 | 2016-08-03 | ラジウス ヘルス，インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
| DK2568806T3 (en) | 2010-05-12 | 2016-08-15 | Radius Health Inc | therapy Programs |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| EP2621901B1 (en) | 2010-09-28 | 2015-07-29 | Radius Health, Inc | Selective androgen receptor modulators |
| EA201391230A1 (ru) * | 2011-02-25 | 2014-01-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов trk |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| MX2015005949A (es) * | 2012-11-16 | 2015-09-08 | Biocryst Pharm Inc | Nucleosidos que contienen aza-azucar antiviral. |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| CA2943611A1 (en) | 2014-03-28 | 2015-10-01 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| SG11201811225RA (en) | 2016-06-22 | 2019-01-30 | Radius Health Inc | Ar+ breast cancer treatment methods |
| KR102881465B1 (ko) | 2017-01-05 | 2025-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| CA3072362A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
| AU2019271129B2 (en) | 2018-05-14 | 2023-03-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CA3098628A1 (en) | 2018-05-17 | 2019-11-21 | Forma Therapeutics, Inc. | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| AU2019297421B2 (en) | 2018-07-04 | 2024-08-29 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD 1901-2HCL |
| RS64321B1 (sr) | 2018-10-05 | 2023-08-31 | Forma Therapeutics Inc | Fuzionisani pirolini koji se ponašaju kao inhibitori ubikvitin specifične proteaze 30 (usp30) |
| CA3128510A1 (en) | 2019-02-12 | 2020-08-20 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| EP3956309A4 (en) | 2019-04-19 | 2023-06-07 | Ligand Pharmaceuticals Inc. | CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND |
| WO2020232119A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2021098810A1 (zh) * | 2019-11-20 | 2021-05-27 | 南京明德新药研发有限公司 | 用作选择性雄激素受体调节剂的化合物 |
| WO2022204184A1 (en) | 2021-03-23 | 2022-09-29 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2025160286A1 (en) * | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411981A (en) * | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2671348B1 (fr) * | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| FR2693461B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| US7649001B2 (en) * | 2002-08-12 | 2010-01-19 | Takeda Pharmaceutical Company Limited | Fused benzene derivative and use |
| WO2004037784A2 (en) * | 2002-10-21 | 2004-05-06 | Irm Llc | Pyrrolidones with anti-hiv activity |
| EP1654221A2 (en) | 2003-06-10 | 2006-05-10 | Smithkline Beecham Corporation | Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
-
2006
- 2006-05-10 AT AT06759481T patent/ATE412647T1/de active
- 2006-05-10 BR BRPI0610183-6A patent/BRPI0610183A2/pt not_active IP Right Cessation
- 2006-05-10 SI SI200630177T patent/SI1891038T1/sl unknown
- 2006-05-10 PL PL06759481T patent/PL1891038T3/pl unknown
- 2006-05-10 CA CA002608419A patent/CA2608419A1/en not_active Abandoned
- 2006-05-10 WO PCT/US2006/018061 patent/WO2006124447A2/en not_active Ceased
- 2006-05-10 ES ES06759481T patent/ES2314922T3/es active Active
- 2006-05-10 JP JP2008511312A patent/JP5089578B2/ja not_active Expired - Fee Related
- 2006-05-10 PT PT06759481T patent/PT1891038E/pt unknown
- 2006-05-10 CN CN2006800165544A patent/CN101175747B/zh not_active Expired - Fee Related
- 2006-05-10 US US11/913,710 patent/US7807691B2/en not_active Expired - Fee Related
- 2006-05-10 MX MX2007014053A patent/MX2007014053A/es active IP Right Grant
- 2006-05-10 DK DK06759481T patent/DK1891038T3/da active
- 2006-05-10 DE DE602006003432T patent/DE602006003432D1/de active Active
- 2006-05-10 AU AU2006247738A patent/AU2006247738A1/en not_active Abandoned
- 2006-05-10 EP EP06759481A patent/EP1891038B1/en not_active Not-in-force
-
2009
- 2009-01-09 CY CY20091100016T patent/CY1108690T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1108690T1 (el) | 2014-04-09 |
| BRPI0610183A2 (pt) | 2012-12-04 |
| WO2006124447A2 (en) | 2006-11-23 |
| SI1891038T1 (sl) | 2009-04-30 |
| WO2006124447A3 (en) | 2007-03-29 |
| US7807691B2 (en) | 2010-10-05 |
| JP5089578B2 (ja) | 2012-12-05 |
| CN101175747A (zh) | 2008-05-07 |
| CA2608419A1 (en) | 2006-11-23 |
| ES2314922T3 (es) | 2009-03-16 |
| MX2007014053A (es) | 2008-02-05 |
| EP1891038B1 (en) | 2008-10-29 |
| DK1891038T3 (da) | 2009-01-19 |
| US20080176864A1 (en) | 2008-07-24 |
| PT1891038E (pt) | 2008-12-02 |
| ATE412647T1 (de) | 2008-11-15 |
| CN101175747B (zh) | 2011-06-22 |
| JP2008540554A (ja) | 2008-11-20 |
| EP1891038A2 (en) | 2008-02-27 |
| AU2006247738A1 (en) | 2006-11-23 |
| DE602006003432D1 (de) | 2008-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1891038T3 (pl) | Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego | |
| SI1902026T1 (sl) | Derivati tetrahidrokarbazola uporabni kot modulatorji androgenskega receptorja | |
| TN2009000189A1 (en) | Tetrahydrocyclopenta [b] indole compounds as androgen receptor modulators | |
| EA201071317A1 (ru) | ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ | |
| MX2009011816A (es) | Derivados de piridina. | |
| TN2011000437A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| NZ593110A (en) | pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| TNSN07384A1 (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
| GEP20135806B (en) | Lactams as beta secretase inhibitors | |
| MXPA05013856A (es) | Agonistas del receptor sht2c para el tratamiento de diabetes y obesidad. | |
| TW200626158A (en) | Naphthaline derivatives | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| MY153733A (en) | Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | |
| MX2010007967A (es) | N-[3-bromo-2-cloro-4-(4,5-dihidro-1h-imidazol-2-ilmetil)-fenil]-m etansulfoamida como agonista parcial alfa-1 a adrenergico para el tratamiento de la incontinencia. | |
| DOP2009000117A (es) | Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos | |
| UA93951C2 (ru) | Производные 2-пиридинкарбоксамида b качестве модуляторов натриевых каналов | |
| PL1817029T3 (pl) | Pochodna izoksazolowa do łagodzenia bólu neuropatycznego |